lancet
17 мая 2019 г. 2:00
[Articles] Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death. Phase 3 trials are needed to conclusively show an overall survival benefit, and to determine the maximum number of metastatic ...
378
Посмотреть видео:
Это интересно!
Комментариев нет
Прочесть полный текст публикации и оставить комментарий могут только зарегистрированные пользователи.